AstraZeneca’s Tagrisso improves overall survival in lung cancer in Phase 3 trial
AstraZeneca has said its cancer drug Tagrisso significantly improved overall survival in a Phase 3 study of patients with lung cancer.
The drug showed statistically significant and clinically meaningful improvement in overall survival in previously untreated patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) mutations.
The safety and tolerability of Tagrisso was consistent with its established profile. The drug is currently approved in 74 countries including the US, Japan and the EU for 1st-line EGFRm metastatic NSCLC.
José Baselga, Executive Vice President, Oncology R&D said: “Today’s positive results show that Tagrisso provides an unprecedented survival outcome versus previous standard-of-care epidermal growth factor receptor tyrosine kinase inhibitors, reaffirming Tagrisso as the 1st-line standard-of-care for EGFR-mutated metastatic non-small cell lung cancer.”
Genentech, a member of the Roche Group, has announced positive results from the phase 3 …
AstraZeneca has announced that it has launched Evinova, its new health-tech business, which it is …